OIPE COS Inventor

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

yontor: Lennart Olsson, et al.

Art Unit.

1644

al Number

10/074,695

Examiner

Saunders, David A.

Filed

: 02/11/2002

:

Title

Receptor Derived Peptides

Involved in Modulation of

Response to Ligand Binding

Confirmation

Customer

Number

9893

Number

23308

CERTIFICATE OF MAILING or FACSIMILE TRANSMISSION UNDER 37 C.F.R. § 1.8(a)(1)
I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria Virginia, 22313-1450, or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Dated: 05/25/2005

By: Som f. Abrian

Printed Name: Joan I. Abriam

AMENDMENT AND RESPONSE TO OFFICE ACTION MAILED 02/25/2005

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Office Action of 02/25/2005, please amend the above-identified application as set forth below, in accordance with revised amendment practice, 37 CFR 1.121, effective July 30, 2003. A complete listing of all claims, replacing all prior claims in the application, and including the text of all non-cancelled claims, is attached.

This Amendment and Response is accompanied by a Transmittal Form, a Power of

<u>PATENT</u> Ser. No. 10/074,695

Attorney Docket No. 5008.02-3-1 Customer No. 23308

Attorney and Change of Correspondence Address and a postcard.

No additional fee is believed to be due. However, in the event that a fee is required in connection with the filing of this Amendment and Response, the Commissioner of Patents is authorized to charge the amount of such fee to Peters, Verny, Jones, Schmitt & Aston Deposit Account No. 16-1331.

Amendments to the Specification begins on page 3 of this paper.

Amendments to the Claims are reflected in the listing of claims which begin on page 5 of this paper.

Remarks/Arguments begin on page 8 of this paper.